Associate Director, Lab Operations

Ginkgo Bioworks is a publicly traded (NYSE: $DNA), high-growth biotechnology company based in Boston’s Seaport District, that is redesigning the living world to solve some of the globe’s growing challenges in health, energy, food, material, and more. Our mission to “make biology easier to engineer” is poised to disrupt multiple industries by leveraging our innovative data, automation, and scale capabilities in biological engineering.

In response to the global COVID-19 pandemic, we have launched a new division: Concentric by Ginkgo. We firmly believe that testing is an essential requirement to re-open the economy as quickly and safely as possible. Concentric is the largest provider of K-12 COVID-19 testing. We currently run state-level K-12 testing programs in more than 10 states and some of the nation’s largest school districts. To date, Concentric has sequenced more than 10,000 samples from a variety of sample types, in support of public health. As we continue to scale Concentric by Ginkgo, our work is also evolving and expanding into new and exciting directions.

#LI-LS2

Note on culture: Concentric by Ginkgo is a high energy, positive and fast paced environment where new challenges and opportunities arise every day, so this opportunity is ideal for people who thrive in those kinds of environments, and for people who like lots of variety in their day. There are lots of opportunities to learn and grow. The team is motivated by doing high impact work in service to society. To get a sense of the culture at Ginkgo, read some articles in Grow by Ginkgo, the company magazine we produce, which tells the story of synthetic biology in a Ginkgo-authentic way.

To learn more about Ginkgo, check out some recent press:

What is it really like to take your company public via a SPAC? One Boston biotech shares its journey (Fortune)

Ginkgo Bioworks resizes the definition of going big in biotech, raising $2.5B in a record SPAC deal that weighs in with a whopping $15B-plus valuation (Endpoints News)

Ginkgo Bioworks CEO on scaling up Covid-19 testing: ‘If we try, we can win’ (CNBC)

Ginkgo raises $70 million to ramp up COVID-19 testing for employers, universities (Boston Globe)

Ginkgo Bioworks Redirects Its Biotech Platform to Coronavirus (Wall Street Journal)

Ginkgo Bioworks Provides Support on Process Optimization to Moderna for COVID-19 Response (PRNewswire)

The Life Factory: Synthetic Organisms From This $1.4 Billion Startup Will Revolutionize Manufacturing (Forbes)

Synthetic Bio Pioneer Ginkgo Raises $290 Million in New Funding (Bloomberg)

Ginkgo Bioworks raises $350 million fund for biotech spinouts (Reuters)

Can This Company Convince You to Love GMOs? (The Atlantic)

We also feel that it’s important to point out the obvious here – there’s a serious lack of diversity in our industry, and that needs to change. Our goal is to help drive that change. Ginkgo is deeply committed to diversity, equity, and inclusion in all of its practices, especially when it comes to growing our team. Our culture promotes inclusion and embraces how rewarding it is to work with people from all walks of life.

We’re developing a powerful biological engineering platform, so we must remain mindful of the many ways our technology can – and will – impact people around the world. We care about how our platform is used, and having a diverse team to build it gives us the best chance that it’s something we’ll be proud of as it continues to grow. Therefore, it’s critical that we incorporate the diverse voices and visions of all those who play a role in the future of biology.

It is the policy of Ginkgo Bioworks to provide equal employment opportunities to all employees and employment applicants.